Wedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and lowers the price target from $33 to $24.
Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and lowers the price target from $33 to $24.